181057-91-0

Basic information

• Product Name: 5-CHLORO-3-(3-NITROPHENYL)ISOXAZOLE
• Synonyms: 5-CHLORO-3-(3-NITROPHENYL)ISOXAZOLE
• CAS NO: 181057-91-0
• Molecular Formula: C₉H₅ClN₂O₃
• Molecular Weight: 0
• Mol File: 181057-91-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-CHLORO-3-(3-NITROPHENYL)ISOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-(3-NITROPHENYL)ISOXAZOLE(181057-91-0)
• EPA Substance Registry System: 5-CHLORO-3-(3-NITROPHENYL)ISOXAZOLE(181057-91-0)

Safety Data

• Hazardous Substances Data: 181057-91-0(Hazardous Substances Data)

Upstream product

• 83256-99-9 3-(3-nitrophenyl)-3-oxopropionic acid methyl ester 
• 52119-38-7 ethyl 3-oxo-3-(3-nitrophenyl)propanoate 
• 103029-79-4 3-(3-nitrophenyl)isoxazol-5(4H)-one 
• 145490-91-1 2-(3-nitrophenyl)-1,1-dichlorocyclopropane 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Nitrosylsulfuric acid in the synthesis of 5-chloroisoxazoles from 1,1-dichlorocyclopropanes

Nitrosylsulfuric acid is shown to be a usable reagent for the synthesis of 5-chloroisoxazoles from readily available 1,1-di-chlorocyclopropanes via nitrosation–heterocyclization reaction. A cytotoxicity of some of the prepared 5-chloroisoxazoles towards M

Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)

The synthesis and biological evaluation of a series of nonpeptidic small molecule antagonists of the human platelet thrombin receptor (PAR-1) are described. Optimization of the 5-amino-3-arylisoxazole lead resulted in an approximate 100-fold increase in potency. The most potent of these compounds (54) inhibits platelet activation with IC50s of 90 nM against the thrombin receptor agonist peptide (TRAP) and 510 nM against thrombin as the agonist. Further, antagonist 54 fully blocks platelet aggregation stimulated by 1 nM thrombin for 10 min.